These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22202425)

  • 1. [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
    Takeda Y; Nakahira S; Takeno A; Suzuki R; Nakata K; Okishiro M; Egawa C; Okamura S; Miki H; Kato T; Takatsuka Y; Tamura S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2496-8. PubMed ID: 22202425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
    Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
    Duan F; Wang MQ; Liu FY; Wang ZJ; Song P
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):716-8. PubMed ID: 20021873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
    Zhang L; Ren ZG; Gan YH; Wang YH; Zhang BH; Chen Y; Xie XY; Ge NL; Ye SL
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):630-3. PubMed ID: 21122420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
    Xu LT; Chen Z; Lin JH; Zhou ZH; Chen H; Meng ZQ; Liu LM
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):703-5. PubMed ID: 21122388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
    Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.